Try our Advanced Search for more refined results
Actelion Ltd.
-
Filed: May 09, 2024 | Entered: May 09, 2024 Actelion Pharmaceuticals Ltd. et al v. Mylan Pharmaceuticals Inc.
835(Patent - Abbreviated New Drug Applications (ANDA)) | West Virginia Northern
Pro Hac Vice Filing Fee in the amount of $600.00 for Robert L. Florence, Elizabeth M. Crompton and Tasneem A. Dharamsi has been paid. Receipt Number: 100003893. (jb) (Entered: 05/09/2024)
-
Order | Filed: May 09, 2024 | Entered: May 09, 2024 Government Employees Health Association v. Actelion Pharmaceuticals Ltd. et al
Anti-Trust | Maryland
Order
PAPERLESS ORDER The Court is in receipt of the parties' joint letter to address the case schedule (ECF No. 332). It is not this Court's practice to set in trial dates before the resolution of pending dispositive motions. The Court will contact the parties, if necessary, following the resolution of the pending dispositive motions, to set in a trial schedule. Signed by Chief Judge George Levi Russell, III on 5/9/2024. (jk6s, Chambers)
-
Motion | Filed: May 09, 2024 | Entered: May 09, 2024 Actelion Pharmaceuticals Ltd. et al v. Mylan Pharmaceuticals Inc.
835(Patent - Abbreviated New Drug Applications (ANDA)) | West Virginia Northern
Motion
MOTION for Leave to Appear Pro Hac Vice (Elizabeth M. Crompton) by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 05/09/2024)
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Archive of over 450,000 articles
- Database of over 2.1 million cases
- 62,000+ organization-specific pages.
- Daily and real-time news and case alerts on organizations, industries, and customized search queries.
- Significant legal events involving law firms, companies, industries, and government agencies.
- Learn more
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login